Clinical trials: Coronavirus Infections
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.
Covid19, Azithromycin
Proactive Care of Ambulatory COVID19 Patients
On January 9, 2020, a new emerging virus was identified by WHO as being responsible for grouped cases of pneumonia in China. It is a coronavirus, SARS-CoV-2, responsible for the disease COVID-19 (Coronavirus disease).
- Conditions
- Covid19, Azithromycin, Ambulatory
- Trial name
- AMBU-COVID (NCT04371107)
- Testing
- consultation, Azithromycin
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Long COVID, Acute COVID-19
Chronic Stress as a Risk Factor for Long COVID
The disease caused by the pathogen SARS-CoV-2 is known as coronavirus disease with the acronym COVID-19. The acute phase of this condition typically lasts one to two weeks and usually results in a full recovery.
- Trial name
- StressLoC (NCT05652634)
- Where
- Austria
- Volunteers
- 380 people
- Sponsor
- Medical University of Graz
COVID-19
The Opal - COVID-19 Study
In collaboration with involved healthcare professionals and a patient advisory committee, this study tests the feasibility of using the Opal smartphone app to daily capture self-reported physical and psychological symptoms and…
- Trial name
- NCT04978233
- Testing
- sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Dr. Bertrand Lebouche
Covid19
COvid Pandemic Institutional maNaGement
Covid-19 has increased organizational tensions within health services (lack of resources, difficulties in recruiting healthcare professionals , elderly and polypathological patients, etc.) and tested the reliability of health…
- Trial name
- COPING (NCT04908007)
- Testing
- Qualitative analysis for professionals, Quantitative analysis for Professionals, Quantitative analysis for Patients
- Where
- 4 sites in France
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Covid19
Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate
The International multicenter FEnofibRate as a Metabolic INtervention for COVID-19 (FERMIN) trial is being executed. The trial is testing a short intervention (10 days of fenofibrate therapy) on 30-day outcomes in COVID-19.
- Trial name
- NCT05080192
- Testing
- Fenofibrate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania
Severe COVID-19
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Multicenter observational retrospective cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic.
- Trial name
- CoVAPid2 (NCT05256511)
- Where
- France
- Sponsor
- University Hospital, Lille
Covid19
COVID-19: Salvage TOcilizumab as a Rescue Measure
Evaluating the efficacy of Tocilizumab in hospitalized patients in the inflammatory phase of COVID-19. Randomization 2:1 (TCZ:standard of care).
- Trial name
- COVIDSTORM (NCT04577534)
- Testing
- iv Tocillizumab (TCZ)
- Where
- Finland
- Volunteers
- 88 people
- Sponsor
- Jarmo Oksi
COVID-19
Study of Efficacy of Different Treatment Regimens of Olokizumab
The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation.
- Trial name
- RESET (NCT05187793)
- Testing
- Olokizumab, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 198 people
- Sponsor
- R-Pharm
HIV, Cardiovascular Diseases
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART).
- Trial name
- REPRIEVE (NCT02344290)
- Testing
- Pitavastatin
- Where
- 137 sites in United States, Botswana and 11 more
- Volunteers
- 7,769 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pregnancy; Mental Disorders, COVID-19 Pandemic
A Telemedicine Prenatal Care Model on Low Risk Pregnants: The m@Mae-e Study
This study will compare the effectiveness of a prenatal care supported by telemedicine against usual care in low-risk pregnant women.
- Conditions
- Pregnancy; Mental Disorders, COVID-19 Pandemic, Prenatal Stress
- Trial name
- m@mae-e (NCT05745896)
- Testing
- Telemedicine appointment, Face-to-face appointment
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Talita Colombo
COVID-19, Respiratory Failure
Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS
The aim of the present study is to examine whether cerebral oxygenation could be a more useful parameter than peripheral oxygen saturation to guide clinical titration of permissive hypoxemia in COVID-19 ARDS patients
- Trial name
- NIRS-COV (NCT04392089)
- Testing
- Masimo, LidCO
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Hvidovre University Hospital
COVID-19
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey
This is a randomized, double-blinded, and positive-controlled Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05150496
- Testing
- Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated, High-dose COVID-19 Vaccine(Vero Cell),Inactivated
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19, SARS-CoV-2
Slovenian National COVID-19 Prevalence Study
The investigators are conducting a national COVID-19 prevalence survey on a sample of 3,000 inhabitants that were randomly selected from the Slovenian population.
- Trial name
- SLO-COVID-19 (NCT04376996)
- Testing
- NO intervention planned due to the observational study design - only a diagnostic testing
- Where
- Slovenia
- Volunteers
- 3,000 people
- Sponsor
- University of Ljubljana
SARS CoV 2 Infection, Cancer
Mortality of Cancer Surgery During SARS CoV2 Pandemic
The impact of cancer surgery during covid epidemic is not clear. The published reports show contradictory findings that extend from no change in mortality to increased mortality, further no data on exposure and outcome of health…
- Trial name
- NCT05240378
- Testing
- Surgery
- Where
- India
- Volunteers
- 1,576 people
- Sponsor
- Banaras Hindu University
COVID-19
Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives
Coronavirus disease 2019 (COVID-19) ,caused by the newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, has shown substantial global spread affecting over 2 million people and claiming over 120,000…
- Trial name
- NCT04357535
- Testing
- Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)
- Where
- Saudi Arabia
- Volunteers
- 314 people
- Sponsor
- Hakeam Abdulaziz Hakeam
Healthy Adult Volunteers
Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination
The investigators conduct a prospective analysis to compare homologous and heterologous adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine inoculation.
- Trial name
- NCT05074368
- Testing
- ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
- Where
- Taiwan
- Volunteers
- 499 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
COVID-19, SARS-CoV-2
The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms
The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus. Multicenter randomized, double-blind, placebo-controlled, non-commercial clinical trial
- Trial name
- COV-PREVENT (NCT04854759)
- Testing
- Amantadine Hydrochloride
- Where
- 8 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Independent Public Clinical Hospital No. 4 in Lublin
Covid19, Corona Virus Infection
T Cells Response to SARS COV 2 Peptides
The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral…
- Trial name
- NCT04573348
- Testing
- Savicell's ImmunoBiopsy™
- Where
- Israel
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Savicell Diagnostics Ltd
Corona Virus Infection, SARS-CoV 2
Kidney in Coronavirus Disease 2019 Registry
The SARS-CoV-2 virus is a virus newly identified in January 2020. The WHO defined COVID-19 as a health emergency of international importance.
- Trial name
- KidneyCOVID19 (NCT04797091)
- Testing
- Retrospective data collection
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Cologne